top of page


Research, Writing and Editing

Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guerette D, Jammal MP, Pickles T, Richard PO, Saad F. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — A Canadian consensus statement. Canadian Urological Association Journal 2018; 12:30-37. [Full text] [PDF]


Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal 2017; 11:16-23. [Full text] [PDF]


Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Annals of Oncology 2015; 10:2044-2056. [Full text] [PDF]


Gill S, Dowden S, Colwell B, Collins LL, Berry S. Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews 2014; 40:1171-1181.


Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Alexander HG Paterson, Robidoux A, Pritchard, KI. Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. Cancer Treatment Reviews 2012; 38:673-688.


Collins LL, Lee YF, Ting HJ, Lin WJ, Liu NC, Meshul CK, Uno H, Bao BY, Chen YT, Chang C. The roles of testicular nuclear receptor 4 (TR4) in male fertility-priapism and sexual behavior defects in TR4 knockout mice. Reproductive Biology and Endocrinology 2011; 9:138. [Full text] [PDF]


Lew BJ, Collins LL, O'Reilly MA, Lawrence BP. Activation of the aryl hydrocarbon receptor during different critical windows in pregnancy alters mammary epithelial cell proliferation and differentiation. Toxicological Sciences 2009; 111:151-62. [Full text] [PDF]


Collins LL, Lew BJ, Lawrence BP. TCDD exposure disrupts mammary epithelial cell differentiation and function. Reproductive Toxicology 2009; 28:11-7. [Full text] [PDF]


Gasiewicz TA, Henry EC, Collins LL. Expression and activity of aryl hydrocarbon receptors in development and cancer. Critical Reviews in Eukaryotic Gene Expression 2008; 18:279-321.


Collins LL, Williamson MA, Thompson BD, Dever DP, Gasiewicz TA, Opanashuk LA. 2,3,7,8-Tetracholorodibenzo-p-dioxin exposure disrupts granule neuron precursor maturation in the developing mouse cerebellum. Toxicological Sciences 2008; 103:125-36. [Full text]


Chen YT, Collins LL, Chang SS, Chang C. The roles of testicular orphan nuclear receptor 4 (TR4) in cerebellar development. Cerebellum 2008; 7:9-17.


Liu NC, Lin WJ, Kim E, Collins LL, Lin HY, Yu IC, Sparks JD, Chen LM, Lee YF, Chang C. Loss of TR4 orphan nuclear receptor reduces phosphoenolpyruvate carboxykinase-mediated gluconeogenesis. Diabetes 2007; 56:2901-9. [Full text] [PDF]


Chen YT, Collins LL, Uno H, Chou SM, Meshul CK, Chang SS, Chang C. Abnormal cerebellar cytoarchitecture and impaired inhibitory signaling in adult mice lacking TR4 orphan nuclear receptor. Brain Research 2007; 1168:72-82. [Full text] [PDF]


Chen YT, Collins LL, Uno H, Chang C. Deficits in motor coordination with aberrant cerebellar development in mice lacking testicular orphan nuclear receptor 4. Molecular and Cellular Biology 2005; 25:2722-32. [Full text] [PDF]


Collins LL, Lee YF, Heinlein CA, Liu NC, Chen YT, Shyr CR, Meshul CK, Uno H, Platt KA, Chang C. Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4. Proceedings of the National Academy of Sciences USA 2004; 101:15058-63. [Full text] [PDF]


Thin TH, Wang L, Kim E, Collins LL, Basavappa R, Chang C. Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment. Journal of Biological Chemistry 2003; 278:7699-708. [Full text] [PDF]


Kim E, Xie S, Yeh SD, Lee YF, Collins LL, Hu YC, Shyr CR, Mu XM, Liu NC, Chen YT, Wang PH, Chang C. Disruption of TR4 orphan nuclear receptor reduces the expression of liver apolipoprotein E/C-I/C-II gene cluster. Journal of Biological Chemistry 2003; 278:46919-26. [Full text] [PDF]


Collins LL, Lee HJ, Chen YT, Chang M, Hsu HY, Yeh S, Chang C. The androgen receptor in spermatogenesis. Cytogenetic and Genome Research 2003; 103:299-301.

Collins, LL,  Chang, C. (2002) Androgens and the androgen receptor in male sex development and fertility. In: Chawnshang Chang (ed.), Androgens and Androgen Receptor: Mechanisms, Functions, and Clinical Applications Kluwer Academic Publishers; pp. 299-323.


Thin TH, Kim E, Yeh S, Sampson ER, Chen YT, Collins LL, Basavappa R, Chang C. Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17beta-estradiol-induced androgen receptor transactivation. Journal of Biological Chemistry 2002; 277:36499-508. [Full text] [PDF]


Shyr CR, Collins LL, Mu XM, Platt KA, Chang C. Spermatogenesis and testis development are normal in mice lacking testicular orphan nuclear receptor 2. Molecular and Cellular Biology 2002; 22:4661-6. [Full text] [PDF]


Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. Journal of Biological Chemistry 2002; 277:36570-6. [Full text] [PDF]


Collins LL, Lin DL, Mu XM, et al. Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16. Journal of Biological Chemistry 2001; 276:27316-21. [Full text] [PDF]


Mu XM, Liu YX, Collins LL, Kim E, Chang C. The p53/retinoblastoma-mediated repression of testicular orphan receptor-2 in the rhesus monkey with cryptorchidism. Journal of Biological Chemistry 2000; 275:23877-83. [Full text] [PDF]


Jung I, Reeder JE, Cox C, Siddiqui JF, O’Connell MJ, Collins L, Yang Z, Messing EM, Wheeless, LL. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. Journal of Urology 1999; 162:1900-3.


Reeder JE, O'Connell MJ, Yang Z, Morreale JF, Collins L, Frank IN, Messing EM, Cockett AT, Cox C, Robinson RD, Wheeless LL. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology 1998; 51:58-61.

Writing and/or Editing (Acknowledged)

Chen YL, Liu KJ, Jang CW, et al. ERK activation modulates cancer stemness and motility of a novel mouse oral squamous cell carcinoma cell line. Cancers 2020;12:61.


Lin HP, Ho HM, Chang CW, et al. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis. FASEB J 2019; 33:14653-67.

Malone S, Shayegan B, Basappa NS, et al. Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal 2019 Apr 26; Epub ahead of print, Epub draft.


Danielson B, Saad F, So A, et al. Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal 2019; 13:420-6.


M. Razanousky, Project Manager. Prepared by: Clarkson University, GE Energy Consulting, Nova Energy Specialists; Edited by: L. Collins. Design of a Resilient Underground Microgrid in Potsdam, NY— New York State Energy Research and Development Authority (NYSERDA) Project 41309, 2018; [PDF download].

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based canadian consensus. Cancer Treatment Reviews 2016; 47:32-45.


Torres S, Simmons C, Boileau J-F, McLeod D, Martins I, Trudeau M. Patterns in target-directed breast cancer research. Springerplus 2016; 5:109.


Pritchard KI, Gelmon KA, Rayson D, Provencher L, Webster M, McLeod D, Verma S. Endocrine therapy for postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Current Oncology 2013; 20:48-61.


Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: Optimizing therapeutic outcomes. Annals of Oncology 2012; 23:2223-2234.


Brackstone M, Robidoux A, Chia S, et al. Canadian initiatives for locally advanced breast cancer research and treatment: inaugural meeting of the Canadian Consortium for LABC. Current Oncology 2011; 18:139-44.


Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Current Oncology 2011; 18: 180-190.

Clinical Symposia Reports

McLeod DM, Collins LL, Smith T, McLeod R, Reece, DE. New developments in myeloma therapy for the elderly: Selected proceedings from the 50th annual meeting of the American Society of Hematology. Clinical Symposia Report: A Canadian Perspective, Volume 3, December 2008.


McLeod DM, Collins LL, Martins I, Topping R, McLeod R,  Reece DE. Evolving strategies for the treatment of transplant ineligible myeloma: Selected proceedings from the 51st annual meeting of the American Society of Hematology. Clinical Symposia Report: A Canadian Perspective, Volume 4, December 2009.

bottom of page